In addition, the performance of natural killer (NK) cells in persons with AML showed that the augmentation of TIM-3 on these cells was related to heightened NK cell activity, eventually leading to improved clinical outcomes in AML patients [23]. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.